Clinical Trial Update: Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CNM-Au8, a therapeutic nanocatalyst, in slowing disease progression for amyotrophic lateral sclerosis has completed and post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• CNM-Au8 (CNM-Au8)

Snippet

Sponsor: Clene Nanomedicine | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2024-07-03